CRVS - Earnings call transcript Q1 2020 | Corvus Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Corvus Pharmaceuticals First Quarter 2020 Business Update and Financial Results Webcast. Please note, today's conference is being recorded. And at this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

pleasure Pure the Communications. my Zack over now of Kubow is to conference turn to It Please ahead, go sir.

Zack Kubow

quarter and Thank you, for first us Thanks for business operator, and good the afternoon, Corvus call. results conference financial everyone. joining XXXX update Pharmaceuticals

some discuss Miller, The the On Richard Mehrdad business highlights XXXX Executive Mobasher, remarks, Officer; executive and Officer; open Leiv prepared Chief results for the the with a and Officer. first team by the will question-and-answer call call quarter Financial Medical to Chief are followed Lea, Chief period.

everyone like to forward-looking comments would today I management and to remind include that will made questions by answers statements.

from filings statements risks materially expressed Corvus' required company and or report Forward-looking makes of or with to on and as uncertainties the publicly as to including assumptions implied by that forward-looking with from those Form those actual revise SEC estimates risks SEC in based law. to today differ described update are statements, and XX-Q any may was uncertainties and to statements quarterly company the no filed subject obligation time today, except and time. by the are other which the cause undertakes on The results

that Leiv? With to to call Leiv the over like I'd turn Lea.

Leiv Lea

XXXX at a Thank Richard to $XX to for quarter with Zack. had then you, XXXX. as totaling December compared I our cash the will At XX, $XX.X cash, marketable call over securities a XX, quick first I'll March of overview quarters begin million equivalents XXXX million update. turn financials and and business

partially million The primarily million by drug to of $X.X reduction $XX.X in manufacturing CPI-XXX XXXX expenses $X.X million period costs. expenses, CPI-XXX in $X.X million offset the XXXX. of development increase totaled Research same million a in trial $X.X compared to the quarter in clinical for increase was due and first

XXXX the million loss loss quarter compared for same of $X first XXXX. net was $XX.X to $XX.X for a compared XXXX. same the the compensation $X.X Total for net of stock period quarter to million for expense million was of The in million period in the XXXX first

that trials Enrollment COVID-XX. we three expenses, of that our less ahead our manage been programs light our cases monitoring pandemic. in allows the on new enrollment in patient has has note continue follow-up by schedule. to to us with and COVID-XX especially of been to some us like I'd carefully affected This dependent on makes focus which in strong,

ability a our ciforadenant. discuss, the impact on impact we our continue Richard minimal will As believe to lead overall advancing have will this program of slowdown

Given the our COVID-XX our situation and towards planned the develop date, our our asset intend deepen we as on XXX trial. pivotal ciforadenant program and enrolled to over lead a we to advancement registration strategy of with head patients focus

in we $XX year of million. result, an now $XX As and of million activities million used a $XX expectations cash cash operating XXXX previous approximate activities expect This is to net between $XX operating reduction be between to full million. in our and compared used net $XX million

to the I'll now Richard. turn call over

Richard Miller

In for and business meetings. Signature therapies. oncology precisely Gene quarter you for patients us Thank on everyone. XXXX joining and our our Enrolling afternoon, good and Leiv, medical ongoing in first of Adenosine updated targeted CPI-XXX the to you, continued quarter update. pipeline our Thank studies ciforadenant, data today advance we first presenting at

and At our clinical safety businesses people most lives changed and the the highest global patients of and is the States. healthcare At Corvus, for pandemic the daily time, that patients health employees, COVID-XX the providers, United to our partners same they in due serve priority.

conducting line protocols sites our to adapt enrolled and disruptions patient clinical studies. pandemic updates the in integrity and made of with the ensuring our our collaborate trials and to on FDA's safety trial communicate during in we to maintaining The for the guidance focused for were quickly worked have potential we studies. COVID-XX accommodate Accordingly, clinical patients with

we addition, sites have drug for to communication significant with I thank manufacturing study would that so our supply. in partnership am no regular clinical minimal been to on difficult In like there a and our their impact during been impact our partners far. pleased this is there currently has our I and trial period

received our follow-up or major To already studies. date, in any treatment we have enrolled for patients not of interruptions reports

variances caring There studies, enrollment detailed the significant of studies. we patients. of clinical an preparing as patients new has impact of shifted has as disease an Specifically, towards on and for instances sites have COVID-XX in monitoring. been such potential There surge been assessments on biopsies, some on-treatment our no missed and on pharmacokinetic in tumor special most safety and impact assessments of

positioning monitoring the on we has Prior of we believe very for of subsequent COVID-XX overall date. the on of COVID-XX, had trials. been not us However, focus to rates emergence now and trials, to impact Corvus primarily to of enrollment all significant our planning in robust

is excellent CPI-XXX an example.

an we the results last presentation interest initial positive on year, ASCO Following in and the saw increase at study enrollments. of from

our schedule. and pembrolizumab, population. we having this of for confirm into a combination With in activity arms program, to completed fourth XX-patient is with triplet arm both our enrollment As ciforadenant we a result, CPI-XXX ahead moved enrollment in the ciforadenant, are designed study tracking which with have already and enrolled of internal in ahead fully pembrolizumab, combination the with third biomarker-positive study of of plans and now

will FDA Of pivotal designing later data ciforadenant a this year now preparation follow-up monitoring meeting with focused our note, data follow-up cell So strategy for the are registration collecting discuss we overall, with on to current renal cancer and in a our in results aim analyzing of our on efforts studies. be and patient analyzing and trial.

is programs. for on approaching inhibitor update very our an a with which the small are this to Turning we receptor, exciting molecule of ciforadenant, our AXA Starting now period program.

for May. renal of in to and most cell Signature to Gene This predictive potential at Adenosine likely data combination ciforadenant will have therapy. an accepted ASCO with key patients treatment late for cancer abstract of provide on respond the the biomarker update We a a for the atezolizumab role this as presentation in

the Our signature independent abstract Signature academic ASCO an enhanced is will leading In renal confirmed. including from study, confirm the in presented that from confidence that potential a that its by value cell Adenosine institution. at groups biomarker be work is other cancer of prognostic in

and to tried or cancer second ciforadenant FDA study design using We later for meet Gene third the third biomarker. a line pivotal discuss renal study the Signature in Adenosine with to quarter in the randomized plans cell

the study single-arm We will for based Adenosine Signature. a be potential exploring also on the

very therapies. the cancer. recall, group subset new positive an do you identifies we do biomarker-identified believe ciforadenant option of a will of cell a with provides renal potential poorly patients, unfavorable better This unmet standard in a area As of need. with and And signature patients

Moving to CPI-XXX, anti-CDXX our antibody. B-cell activating

this has circulating be demonstrated on dramatic novel B-cell to cells about redistribution. immunomodulatory effects continue and enthusiastic antibody, and with immune mobilization T-cell which We

We are not targeting other aware antibody of these or that molecule agent exhibited any has properties. small CDXX target other any

antibodies. have plasmablast previously reported, CPI-XXX has effects and IgG we transformation to IgM As profound and to of leading on secretion B-cells activation,

triplet this in We at work year. with November ciforadenant, XX meeting In evaluating total, enrolled antibody the a to combined pembrolizumab. combination over the present in in which ciforadenant SITC pembrolizumab study, with and is we patients later in our to and update date CPI-XXX on this intend with alone combination have an

the enhance use potential as area antibody new One tantalizing to responses. a is CPI-XXX therapy to

occupancy treated have optimal safety, have We of dose antibodies its anti-tumor Last, patients our established some ITK activity. and in our we of receptor on pharmacokinetics seen produced cancer with with CPI-XXX signs along early CPI-XXX. inhibitor, anti-tumor

first of study, forward study lymphoma. the initial patient the plan we next X/Xb portion on an cutaneous focus on of the responses from with to the Phase move T-cell Based portion with

but providing not PK has also and in So the occupancy. succeeded important trial future target now selectivity in for about positions in only autoimmune diseases. far studies us information this This well dose, lymphoma

to progress continue our with good we summary, In pipeline. make

We have the of a efficient use programs clinic. with across accomplished capital in this three very

a step Adenosine cell with an towards of in the ciforadenant XXXX. that the look on of Gene data forward We time. presentation this early ASCO. We'll with update in to we at the make program pivotal used Importantly, to have at initiate important an the Signature study renal cancer latest potential providing

now for questions the and turn operator call answers. to I Operator? will over the

Operator

Thank today Mizuho. will with question Goldstein from first Our [Operator Mara come Instructions] you.

Richard Miller

Okay. Mara?

Operator

line your is Hi, open.

Sorry about that.

Mara Goldstein

a for a Is that when enrolled the then for understanding path inhibitor not Just just ITK next and it triplet into couple fits think you that trial you curious the and yet? have paradigm? fully into CDXX, about And the but the scenario comparator, ciforadenant treatment of terms in on might clinical be in questions clinical I'm of first sort in pembrolizumab. the one combination is just What about advancing and would most likely the of and that -- drug? how

Richard Miller

Is the it end that what? didn't I -- that? Is catch of

Mara Goldstein

of that sense enrolled the kind that yet? In fully give just Is one us you -- a of... ciforadenant can

Richard Miller

Okay. The almost fully treatment is enrolled.

think, one two been if here, or identified. it missing still in within That but I they've the go next fully we jump all patients in have and will week to I'm enrolled Mehrdad be or something X.

the... So

Mehrdad Mobasher

accurate. you're No

Richard Miller

Yes.

So done. that's

question that that's and approved has patients think we've who -- -- study now every failed been the the all in how about I our about everyone, So patients think to to has for actually done been enrolled it? diseases. patient those been ITK of that fully so first enrolled, agent that. the Did date who

T-cell the in patients patients. in in lymphoma therapies our lymphoma no noteworthy these quite are for cutaneous see patients other sick. because we and activity any patients are studies there So T-cell is These

put elaborate to bit that further. Just a little

a there's As therapies you know for lymphomas. lot of

have most it recent of lymphomas, have them. on Some but patients coming some kinds they with And trial our for these minimal curative activity. of is

up. lines are fact with greater than pretty deed In so these therapy, prior patients of five

activity think we that treating noteworthy. been So – activity that the we've any is patients in

we've about immune We've target our and emphasize been Of and this target is that. system of trial the Phase like which safety And the aspect. study leaned trial important portion done the tremendous course determine and dosing to every aim effects we've to the these say has lines the of of occupancy and our on along -- the I I has succeeded and things drug.

And to is. we target of a blocking there specific specifically in knowledge ITK that has inhibitor on and never particular, been very learning the what our impact are

we're what -- that's So that. on

Mara Goldstein

you just And Okay. XXX to full? those -- selection confirm of

Richard Miller

going we're XXX with milligrams... So forward

Mara Goldstein

a had have trial kind going the okay. are sense failed -- And PTCL begin to study you You so you'll fact do what that size these just looking around population and given the that of that to for... with be therapies have of patient patients size many are, you

Richard Miller

before all we're Xb part to -- try the even this. we of first in still So well of

is XXX patients. the and very then from some and thing activity the feel more that, The we're so going been nice design to So it's go going far. we'll get trial for about We're a treat to new there. safe

have now some treatment on every And this for for day patients been months months. several

our to single And so as this very agent. about Mara as therapies are of attractive it's combinations. But a think most you lymphoma know now only not

And treatment earlier in it up kind how so we're now of about to what beginning also et you together therapies with to it put move think the paradigm cetera.

Mara Goldstein

right. hop somebody back. Thanks. with all off will else Appreciate, Okay, I

Operator

Your next question come Butler Roth will with Capital. Tony from

Tony Butler

first of enrolled CPI-XXX couple me So the to cohort I as be among cohorts. course Is clinical actually were patients a questions Richard, well. the want wrong presumption correct study. Xc XaXc? of to And correct? Xa and cohort that back equally go that if that's of within trials those in the divided there I'm And question. six is XXX to

And ciforadenant fourth then which in trial the presumed you next again -- registration the registration year RCC. to the for second, or start hope line question of second third from

very or throw it And you you with just do just conjunction? what used So a you single registration what do be And in use trial. think form patients this from a of curious takes? Atezo much. you a about also increasingly be you both I'm simply and/or control Will previous been all standard those you as PD-X plus obviously know having -- care one Thanks cifo, Is how the is think have Signatures. that do standpoint. you and Adenosine failures or will how curious front-line. Atezo that from of standpoint -- I'm would regardless

Richard Miller

Okay.

So to you Mehrdad, both questions? do have want actually those of

Mehrdad Mobasher

Sure.

of do what that have is But front the terms Almost right. not in signature now patients the get remember patients to in is question you're immunotherapy identifies the in immunotherapy. who signature PD-Xs second all landscape, to do frontline are going we this line. The shown the well

and also So answer we resistance these of rescued. it mechanism Did patients. ciforadenant is from what will given giving them in I are The we mode powered that's signature-positive action with the be is the will second we And study that know are for the will and what how doing that for PD-X, be your PD-LX combination be patients idea question? those.

Tony Butler

So maybe if…

Leiv Lea

Go Richard. ahead

Richard Miller

answers. [indiscernible] ahead Go

Tony Butler

No. No. Go ahead.

think you fine. I answer. did That's

Richard Miller

around [indiscernible] we're think positive. I

I after it I first that's But clinical the if everything basically question added some So trials.gov. on we get to this and up Tony can't -- was because started. cohorts remember

There So in cohorts. that study. with basically there the are merge the four XXX pathway. idea monotherapy, together being in two adenosines the brought ciforadenant four were cohorts XXX we

of element third The the cohort XXX triplet almost for enrolled we We've three the final except is together fourth mentioned a now was earlier. cifo those as is enrolled and pembro. all the doublet with XXX arm And all of pembro. which

staggered the were up monotherapy went IV of a you the weeks So per every but those the milligrams right cohorts one we to in kilogram safety because although of in bit milligrams all combinations establish after the founding escalation We XX they each per and there milligram have were each to kilogram few dose per across board. to XX kilogram. from for be found dose

using that's the the four base for So of cohorts. each we're

there's to to Now cell ability extend category. within the there's think prostate an they're and and I other cohorts renal and at lung each those of -- look

monotherapy. been of four buckets -- combination is tended can the our the more this So of one the many we as that enrolled of four at But there's patients And like that's looking conducting have of to because arms. over, the each beauties we've sort patients for to we've trial shift those. maybe trial versus carefully the over getting maybe find of we

maybe we're going and more combinations show cohorts, of necessary four to every some of are So, every not up that the think important. don't seen we bucket that's because evidence we've

Tony Butler

is Agreed. better me we've And believe had the may continue to-date. but I which triplet demonstrated that in of actually if theme. data I'm it the if just wrong, population seen Correct often some I small that on

patients, but want understand to that can confirm as I shift seeing that why well. you So was what you I just were

Richard Miller

data is triplet is cohorts have enough the the yet. been Well, The -- we've enrolling. that the don't we last of triplet

on that we of and least like has time, on XX There So data, patients therapy. this that least the point but of at in are as now. the active on. will over patients this mature go something course number mature Still trial

the I in past work his because in one or of -- and -- safety now to So is enrollment the our at that start make data run tried really stack we've we and tank efficacy things good patients emphasized emphasize and the decisions. these now been to We've data to this execution is and look year start our really -- and treat a loaded the so And progress. Leiv so introduction and biomarker has loaded and can the fuel some the over two. and

enrollment impacted before And unfortunately from needed of I most very we this really pandemic think has COVID because that's why don't gotten we have what much, happens. us that

it's now a this matter of data mature. letting so And

therapy patients trials. We now our lot across have of a on

question answers. said, the after mature figure next it. a it's I out that make we steps go analyze Does likely sense? getting to as the Now And of

Tony Butler

it Richard. Yes, Thank you appreciate did. I Mehrdad very it. much

Richard Miller

say any if there's which four is is -- so But proof the of there's a proof that yet? better. So ask combination of I there's me, you you me, suspicion ask I no a -- wouldn't better to the mean, which of of cohorts that.

now profound. even trafficking And a on at that of way. on a the It's absolutely humoral immunity on no immune really really, amazing. question, kilogram. the The absolutely one one very impact positive impact milligram dose is no B-cells on that system. is per occurs in But We lymphocyte thing believe -- no question is

in has new There's not never before not and that This we but effects we been vitro see here adenosine. biology it's the even out adenosine out, be seen. described take to can't rule of is when that about equation. going I these

block protein was CDXX way back reacting the XXX adenosine to which that. CDXX part antibodies And not effect, immunostimulatory is described knew an reacquisition other that different first It's has also of with we that. the a XXXXs. antibody by in episodes. Recent have We that about production the

don't think other or that any this property. our molecule we we knowledge, small to antibody seen has don't or anybody that about we've So any heard think

Tony Butler

Richard, the thank you color. very much. Appreciate

Operator

H.C. Our question Swayampakula Instructions] with [Operator from next Ramakanth Wainwright. will come

Swayampakula Ramakanth

you, nevertheless ask you you. let Thank afternoon? questions. you this, answered Thank Richard. How but doing are this this. Since you jumping I couple I've have of been have calls, might me between

ciforadenant program Phase the study, Xb/X data expected the there So ASCO. on at was in some

the what, that we beyond And So study about? conference? of, Xb/X should that the data also you're forward Phase what's expect at path sort talking

on is the data What's for study. time what And line question second from development -- of next process the for here? The expectations Xb Phase there? the XXX the the for is

Richard Miller

Okay.

with me let start to well. might ask comment ciforadenant I So Mehrdad and the then as

that we recall who is in published with renal regression. a resist patients had rate data author. showed were first So many in we cancer. on in also mostly Signature PR patients paper, positive failure tumor cell discovery substantial by He refractory advanced that There was quite from criteria the PD-X for Larry cancer XX% were use published there response patients in who the criteria. Adenosine And didn't January XX UCSF that Fong

survival was population. curve. zero, responded, -- a Signature nice We And also and statistically significantly Signature-negative plateau with the long-lived that there nobody the showed not a that plateau, on in progression-free was Adenosine associated Adenosine was

prospectively the in this observation of let's said, knew course, And publication an January. we about we, now, data prospectively we this is before that. Well corroborate let's okay,

And out patients. XX enroll to we approximately set so

Adenosine data And but both Signature-positive the think additional additional not that XX with positives for the follow-up the those again And the we negatives. those some be can it's confirm have negative. enrolled follow-up have, on patients we And up. very we've I again and abstract. going to of to hold expected the only for it short are I those a or nicely. I Plus The XX patients going mean subject are we our XX up XX, additional -- surprise. is That holding not be patients. ASCO the to is And It's up. holding so. data of to

nice of what's ASCO I workers us of in I they Adenosine independent the a very I if what at looked say those we Adenosine mentioned And can find are and outcome. invention have in hundreds bad name these your of at course you're use Signature-positive, exactly paper very not where of patients the standard they remarks and do. with Sloan-Kettering basically my therapy. treated That's addition said they you guess Sloan-Kettering there's In -- Signature as at patients the That patients prognosis and if -- the by antagonists.

feel good pretty So signature we now. about the

in that for -- trial. so us a Now sets terms up biomarker-defined

should cell I about we've Now, initial we XX% that, are found, renal of Adenosine cancer patients also say our in with found work Signature-positive.

most our recent think XX%. I is data like

same in it's So the neighborhood.

XX% two-third so probably patients it's or So of signature-positive. or are

a And very and months. of we can the those sets in do – it's don't that take and everybody, – is to. that so other analysis the we'll work is our poorly where disease, are substantial up very Sloan-Kettering that be just work for is talked trial, this where we've hierarchical we companies any I And that fraction the do question this think So some have poorly. sort things work a do because coming new some We there's population focus signature-positives. nice the our they patients. they can can of in. on identified drug active so And now. And the of deciding frankly options us we've we a

cancer. would top trial. protocol. But a in in randomized field the experts well way. and Dr. renal There's people the cell Mobasher on that They're define pivotal the – is a There's working with

just So, then I'll more comment you Mehrdad that. on let do talk generally our him about some what that. want are on to plans

Mehrdad Mobasher

Yeah. Yeah.

we mentioned, patient our initial new that who have treatments. would population COVID they the data, need that we As are think actually based identified patients on the treatment. on the we benefit data from plans And our these based this

steering formed have So we committee.

signature patients. is we that meaningful on think And the working path. that's that be will That path are data without our pivotal discussed the powered We be will in party. a

Swayampakula Ramakanth

Thank you, Richard and thank you, Mehrdad.

Richard Miller

right. All

time on also you about – XXX Now asked line. the

but our the time cutaneous line enroll appropriate So argument the to you drug, the focus at starting patients more. on we're we lymphoma frankly, also T-cell very for an some with to of applications. are but to enroll going as bit disease people we're the is this other more NIH that to because We're that. interesting very We're some to here. interested very, we're only, a other don't very disease XXX could self, at following the We that's begun study example. lymphomas T-cell little a certain now. that with people going think collaborating be think immune patients some immunity. so getting more are disease in We're well, look for this trying might make enroll in with We patients in other a we've work And area, other much as

I to might us an on ASH place things see we'll So good be how that, think update there. go for a but give meeting

Swayampakula Ramakanth

Appreciate that, Thanks. Great. Richard.

Operator

Thank you.

with we'll from Gabriel hear Mizuho Next, Securities. Fung

Gabriel Fung

that's – you think How XX%. Adenosine this the that directly XX% of patients think from mentioned Mehrdad. it do follow-up you corner. to compared on, sorry Signature-selected pivotal that Approximately And that pivotal mean, outcome be what that will good given guys. used already the program are It's the a how to you for think around a Mizuho on adenosine-positive. do this for just Do actually will This Gabriel Hello, arm? the be is I And to opportunity? in maybe ciforadenant with Securities be a works to study. earlier lines you – could Mara. market Congrats actually be hear change required you in Yeah. addition if the said team. results will

Richard Miller

you. Thank

that? So, . do take to you want Mehrdad,

Mehrdad Mobasher

Sure.

they patients. tail objective are who one suggests every In responses. curve. health From committee until pretty just operational we viable and authority. All also be long of mentioned options. actually And patients terms that ones duration given earlier, that that And of whether that in signature-positive a would is the be now the has – as have the with or with enrolling enrolling cooperation Richard signature-positive survival data would have the us study actually fine-tune are a both progression-free are that steering in fairer our trying perspective, to what the

I that the answered first question. the way think was I it. your part of That's

rescue And second and a we getting But landscape to of future. mode to respond well frontline, would move treatment. treatment third-line that for of focus will in on. this are the looking background that's patients whatever early think want not typically, for the action, And There with combination the part, be these is is potential this because patients perfect these treatment in they again something is ciforadenant, But patients, in second-line to oncology be in as immuno-oncology on in a are terms well, who into we're treatment we treatment. the are believe but based respond patients our you will our the that and not would now.

Richard Miller

Yeah, that's add -- like to Mehrdad. would to to that. good a just I point,

nice the data over XXX we of One and about things have now patients. like ciforadenant

a have drug now this for taking year. who've We been over patients

I have every two years over we think some day.

Mehrdad Mobasher

years. Three

Richard Miller

you're – years Mehrdad. older sorry, thought than Three I

very this a line be front easy been So asked this would very, to with safety drug and standpoint from already stuff. combine about we've

late-line in the move earlier. it approval So drugs there's try like get then no we and question to there up many we

the quickly. is are cancer very expands. like lot. living of Patients is They the lymphomas becoming And landscape Now in chronic make third, changing fourth, Obviously, sense. second a changing a a renal somewhat that longer. fifth lines It's it therapy. cell

but about you're entrance four to the years is we Now start is this ago. predicted or to not had going prevalence, when the something the probably disease, you point And prevalence think in of three increase. actually the

tumors. terms looking I market in company, Signatures Adenosine in attractive. Certainly the as been of market, renal for good. forget But we've a other small at think so very us that. very, Now it's cell would for the don't And the be

have distribution In Hotson looking by was that at tumors. Hwang from is Adenosine shows -- the just has is submitted fact, we Signature data. for a the present that paper in Steven TCGA Drew publication and looked and R. that other that at And it of

to us it use be or So drug signature. that to tumors leaves -- applicable of the on which will identify the based

would or renal that's So future. to this for work wouldn't all wrong think I to very it I But just similar in be cell the of a very, The is this, limit therapy. similar more think cancer very just -- as be those. done biology

Mehrdad Mobasher

Right.

Richard Miller

myeloid be our And see published Adenosine haven't it's ASCO infiltrates, presentation. and and other related of myeloid the this infiltrates. I people to going abstract, you'll yet. refer is one identified in on to our as myeloid cell guess abstracts our other in Signature cell the abstract If things And just -- signature. to independently we've things Other those cells that's

not cancers just other there are as well. immuno-cell are myeloid those many cells cancer So

of on of It application say is Identifying happen subset this So new outside to every based just day. of a biomarker. the the in back doesn't would potential a I up a tumors But second. the renal. upside disease

scientific clinical team and we team now and very cancers and that, these deal biometrics team, my is disease talk a that's career. how that makes a identifying a a about versus new think about you category In academic move. And medicine proud other think about so of of non-squamous. and And big you a I'm career-making squamous

to because the to the to morphologic was, like then diseases day were different when diffuse was we from non-Hodgkin's drugs this biological lymphoma. opportunity determine things differentiate what bunch therapy that were you're a know day Again, Again, follicular and diseases didn't large clinical you're to difference a was could we lymphoma. didn't guided lymphoma real Well what develop differentiate characteristics. there different we differences gave lymphoma Hodgkin's there and breakthroughs of B-cell these a those these when for. it look know were with Otherwise, the greater in that treating what you and going took

big, So deal. that's big a

we're And got cure make that drugs do. to to to we've that's Now it. trying what try

Gabriel Fung

because sense what follow-up, from What I Awesome. programs you they know [Indiscernible] Actually cancer really and are prostate. that around leads your me you not are to are wrapped -- quick also have a those?

Richard Miller

we that on presented ago. well of couple So in see prostate, activity We prostate. just months a data

those what people treatment. long-term -- for I With work them. on is other prostate good Again, we're area. more that trial, do outcome are that patients think There's reporting We're we're we're what in in I'm some the activity in sure lots that on patients. is to area, but looking We'll prostate. now. looking following not right competitive interested probably that of our

enough just be good not to it's active. So

You have to have some advantage.

on and we're most Genentech. lung patients with program these the cancer, following -- on the of So

that some present I patients, It's to I'm don't expect from small not know I ESMO. there's about that. number a of think that. data what sure at really plans to maybe so

Gabriel Fung

it. Got you. Thank

Richard Miller

All right.

Operator

And this closing in queue. no remarks. speakers the further our questions conference to have I'll back or turn over we time our for additional at any

Richard Miller

operator. you, Thank Okay.

time. to with First of happy look thank and very you us enjoyed you Thank We're we for ASCO at very giving much This that all, this unusual today. future forward is you some joining I call. and soon that. participate much. updates in speaking of you all very could beyond

Operator

conference our today. your for Thank you. for does conclude participation. We that you thank And

Corvus Pharmaceuticals (CRVS) 2 May 202020 Q1 Earnings call transcript